Review article: how and when to use ciclosporin in ulcerative colitis

被引:36
作者
Durai, D [1 ]
Hawthorne, AB [1 ]
机构
[1] Univ Wales Hosp, Dept Med, Cardiff CF4 4XW, S Glam, Wales
关键词
D O I
10.1111/j.1365-2036.2005.02680.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although colectomy for ulcerative colitis is curative, long-term quality of life is reduced. Intravenous ciclosporin 4 mg/kg/day has significant toxicity. There is now evidence that low-dose ciclosporin (2 mg/kg daily by intravenous infusion, or 5-6 mg/kg daily in a twice daily oral dosage) has an acceptable safety profile, even when used in combination with corticosteroids. Drug dosage should be adjusted to the levels of 150-250 ng/mL initially (random levels during intravenous infusion, or trough levels for oral use). Ciclosporin should be considered not only in those who have failed 7 days of corticosteroids, but also in fulminant colitis at day 3, if not responding to corticosteroids. The drug should be avoided in frail or elderly patients with significant comorbidity, and also where colectomy is likely to be necessary in the short to medium term. Ciclosporin should not be continued for more than 7 days, unless there is a definite response. A 70-80% initial response is likely, and responders are discharged on oral ciclosporin, adding thiopurines and tailing prednisolone rapidly. The drug should be continued for 3 months. The likelihood of avoiding colectomy over 2-3 years is 40-50%. More studies are needed to evaluate the use of oral ciclosporin in corticosteroid-refractory colitis in out-patients, and to assess whether monotherapy (without corticosteroids) is significantly safer, without loss of efficacy.
引用
收藏
页码:907 / 916
页数:10
相关论文
共 53 条
  • [1] Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis
    Actis, GC
    Volpes, R
    Rizzetto, N
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (08) : 905 - 908
  • [2] Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: An open-label retrospective trial
    Actis, GC
    Aimo, G
    Priolo, G
    Moscato, D
    Rizzetto, M
    Pagni, R
    [J]. INFLAMMATORY BOWEL DISEASES, 1998, 4 (04) : 276 - 279
  • [3] [Anonymous], 1997, ELLENHORNS MED TOXIC
  • [4] Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Arts, J
    D'Haens, G
    Zeegers, M
    Van Assche, G
    Hiele, M
    D'Hoore, A
    Penninckx, F
    Vermeire, S
    Rutgeerts, P
    [J]. INFLAMMATORY BOWEL DISEASES, 2004, 10 (02) : 73 - 78
  • [5] Prognosis of severe attacks in ulcerative colitis:: effect of intensive medical treatment
    Benazzato, L
    D'Incà, R
    Grigoletto, F
    Perissinotto, E
    Medici, V
    Angriman, I
    Sturniolo, GC
    [J]. DIGESTIVE AND LIVER DISEASE, 2004, 36 (07) : 461 - 466
  • [6] Ciclosporin use in acute ulcerative colitis: a long-term experience
    Campbell, S
    Travis, S
    Jewell, D
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (01) : 79 - 84
  • [7] Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome
    Campbell, S
    Ghosh, S
    [J]. DIGESTIVE AND LIVER DISEASE, 2003, 35 (08) : 546 - 551
  • [8] Intravenous cyclosporine in attacks of ulcerative colitis - Short-term and long-term responses
    Carbonnel, F
    Boruchowicz, A
    Duclos, B
    Soule, JC
    Lerebours, E
    Lemann, M
    Belaiche, J
    Colombel, JF
    Cosnes, J
    Gendre, JP
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : 2471 - 2476
  • [9] Caroli A, 2000, AM J GASTROENTEROL, V95, P3016, DOI 10.1111/j.1572-0241.2000.03239.x
  • [10] Cohen RD, 1999, INFLAMM BOWEL DIS, V5, P1